drugset
drugset / Trial / NCT04081857

A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

NCT04081857 ↗

Phase 1 Completed 48 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics and safety of HCP1704 in healthy subjects.

Timeline

Start
2019-06-03
Primary completion
2019-08-05
Completion
2019-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1704 Unknown — —
Subject HGP1810 Unknown — —

Indications

No indication recorded.